Inhibition has been shown to exert an anti-tumor effect, however, only in immunocompetent mice, suggesting that the anti-tumor activity of HDAC6 inhibitors (HDAC6i) requires an intact adaptive immune system [147]. This evidence concerns the gene HDAC6 and neoplasm.